文献情報

  1. トップページ > 
  2. 文献情報
NEW
Topical Sirolimus 0.2% Gel for the Management of Tuberous Sclerosis Complex-Related Cutaneous Manifestations: An Interim Analysis of Postmarketing Surveillance in Japan
Dermatol Ther(Heidelb).2023 May;13(5):1113-1126.
メール PubMed
Characterization and management of facial angiofibroma related to tuberous sclerosis complex in the United States: retrospective analysis of the natural history database
Orphanet J Rare Dis. 2022 Sep 14;17(1):355.
メール PubMed

Impact of facial angiofibromas in tuberous sclerosis complex and reported efficacy of available treatments
Front Med (Lausanne). 2022 Aug 29;9:967971.
メール PubMed

爪囲線維腫から診断に至った結節性硬化症の母子例
丸田 志野,他 臨床皮膚科 2021年 75巻13号 Page1081-1087
メール 医書.jp

Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations
Hope Northrup, et al. Pediatr Neurol. 2021 Oct;123:50-66.
メール PubMed

Topical rapamycin in the treatment of facial angiofibromas in tuberous sclerosis: a systematic review based on evidence
Clara Cortell Fuster, et al. J Dermatolog Treat. 2021 Apr 6;1-7.
メール PubMed

診断時に顔面血管線維腫を主症状とし,シロリムスゲルが皮疹に有効であった結節性硬化症の2例
関根 史織,他 皮膚科の臨床 2021年 63巻1号 Page101-104
メール 医書.jp

葉状白斑にシロリムス外用が有効であった結節性硬化症の1例
内田 理美,他 皮膚科の臨床 2020年 62巻8号 Page1211-1214
メール 医書.jp

Improved health-related quality of life in patients treated with topical sirolimus for facial angiofibroma associated with tuberous sclerosis complex
Takashi Hatano, et al. Orphanet J Rare Dis. 2020 Jun 1;15(1):133.
メール PubMed

Safety and Efficacy of the Sirolimus Gel for TSC Patients With Facial Skin Lesions in a Long-Term, Open-Label, Extension, Uncontrolled Clinical Trial.
Wataya-Kaneda M, et al. Dermatol Ther (Heidelb). 2020 May 8.
メール PubMed

Early Sirolimus Gel Treatment May Diminish Angiofibromas and Prevent Angiofibroma Recurrence in Children With Tuberous Sclerosis Complex.
Okanishi T, et al. Front Med (Lausanne). 2020 Jan 22;7:1.
メール PubMed

Sirolimus Gel Treatment vs Placebo for Facial Angiofibromas in Patients With Tuberous Sclerosis Complex: A Randomized Clinical Trial.
Wataya-Kaneda M, et al. JAMA Dermatol. 2018; 154(7): 781-788
メール PubMed

Efficacy and Safety of Topical Sirolimus Therapy for Facial Angiofibromas in the Tuberous Sclerosis Complex : A Randomized Clinical Trial.
Wataya-Kaneda M, et al. JAMA Dermatol. 2017; 153(1): 39-48
メール PubMed

Clinical and Histologic Analysis of the Efficacy of Topical Rapamycin Therapy Against Hypomelanotic Macules in Tuberous Sclerosis Complex.
Wataya-Kaneda M, et al. JAMA Dermatol. 2015; 151(7): 722-730
メール PubMed

Improvement of tuberous sclerosis complex (TSC) skin tumors during long-term treatment with oral sirolimus.
Nathan N, et al. J Am Acad Dermatol. 2015; 73(5): 802-808
メール PubMed

Topical 0.2% rapamycin to treat facial angiofibromas and hypomelanotic macules in tuberous sclerosis.
Knopfel N, et al. Actas Dermosifiliogr. 2014; 105(8): 802-803
メール PubMed

Successful treatment of subungual fibromas of tuberous sclerosis with topical rapamycin.
Muzic JG, et al. JAMA Dermatol. 2014; 150(9): 1024-1025
メール PubMed

A novel application of topical rapamycin formulation, an inhibitor of mTOR, for patients with hypomelanotic macules in tuberous sclerosis complex.
Wataya-Kaneda M, et al. Arch Dermatol. 2012; 148(1): 138-139
メール PubMed

Rapamycin therapy for renal, brain, and skin lesions in a tuberous sclerosis patient.
Micozkadioglu H, et al. Ren Fail. 2010; 32(10): 1233-1236
メール PubMed

Rapamycin as a therapy of choice after renal transplantation in a patient with tuberous sclerosis complex.
Tarasewicz A, et al. Transplant Proc. 2009; 41(9): 3677-3682
メール PubMed

Topical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model.
Rauktys A, et al. BMC Dermatol. 2008; 8 : 1.
メール PubMed

ページのトップへ

サイトマップ    個人情報保護方針    個人データ保護方針(GDPR版)    サイトポリシー    ご利用にあたって    会社概要

Copyright © Nobelpharma Co.,Ltd. all rights reserved.